Rankings
▼
Calendar
JAZZ Q1 2018 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$11B
Q1 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$445M
+18.2% YoY
Gross Profit
$411M
92.4% margin
Operating Income
$88M
19.7% margin
Net Income
$46M
10.3% margin
EPS (Diluted)
$0.75
QoQ Revenue Growth
+1.9%
Cash Flow
Operating Cash Flow
$162M
Free Cash Flow
$155M
Stock-Based Comp.
$24M
Balance Sheet
Total Assets
$5.3B
Total Liabilities
$2.5B
Stockholders' Equity
$2.8B
Cash & Equivalents
$453M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$445M
$376M
+18.2%
Gross Profit
$411M
$351M
+17.0%
Operating Income
$88M
$136M
-35.5%
Net Income
$46M
$87M
-46.8%
Revenue Segments
Product And Services, Product Sales
$441M
50%
Xyrem
$317M
36%
Erwinaze And Erwinase
$51M
6%
Defitelio
$35M
4%
Vyxeos
$26M
3%
Prialt
$6M
1%
Other Products
$6M
1%
Product And Services, Royalties And Contract Revenue
$4M
0%
Geographic Segments
UNITED STATES
$406M
91%
Europe
$28M
6%
Other Countries
$11M
2%
← FY 2018
All Quarters
Q2 2018 →